CO5650254A2 - Compuestos n-[4-sustituido piperazin-1-sulfonilmetil-alquil]-n-hidroxiformamida como inhibidores de metaloproteinasa - Google Patents

Compuestos n-[4-sustituido piperazin-1-sulfonilmetil-alquil]-n-hidroxiformamida como inhibidores de metaloproteinasa

Info

Publication number
CO5650254A2
CO5650254A2 CO05130352A CO05130352A CO5650254A2 CO 5650254 A2 CO5650254 A2 CO 5650254A2 CO 05130352 A CO05130352 A CO 05130352A CO 05130352 A CO05130352 A CO 05130352A CO 5650254 A2 CO5650254 A2 CO 5650254A2
Authority
CO
Colombia
Prior art keywords
alkyl
ring
replaced
aryl
sulfonylmetil
Prior art date
Application number
CO05130352A
Other languages
English (en)
Spanish (es)
Inventor
Maurice Raymond Verschoyle Finlay
David Waterson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27656653&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5650254(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO5650254A2 publication Critical patent/CO5650254A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
CO05130352A 2003-06-27 2005-12-27 Compuestos n-[4-sustituido piperazin-1-sulfonilmetil-alquil]-n-hidroxiformamida como inhibidores de metaloproteinasa CO5650254A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0301922A SE0301922D0 (sv) 2003-06-27 2003-06-27 Novel compounds

Publications (1)

Publication Number Publication Date
CO5650254A2 true CO5650254A2 (es) 2006-06-30

Family

ID=27656653

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05130352A CO5650254A2 (es) 2003-06-27 2005-12-27 Compuestos n-[4-sustituido piperazin-1-sulfonilmetil-alquil]-n-hidroxiformamida como inhibidores de metaloproteinasa

Country Status (33)

Country Link
US (1) US7485644B2 (OSRAM)
EP (1) EP1644340B1 (OSRAM)
JP (1) JP4701167B2 (OSRAM)
KR (1) KR20060026440A (OSRAM)
CN (2) CN102229589A (OSRAM)
AR (1) AR044931A1 (OSRAM)
AT (1) ATE414063T1 (OSRAM)
AU (1) AU2004251104B2 (OSRAM)
BR (1) BRPI0411929A (OSRAM)
CA (1) CA2529468A1 (OSRAM)
CO (1) CO5650254A2 (OSRAM)
CY (1) CY1108757T1 (OSRAM)
DE (1) DE602004017733D1 (OSRAM)
DK (1) DK1644340T3 (OSRAM)
ES (1) ES2315675T3 (OSRAM)
HR (1) HRP20090009T3 (OSRAM)
IL (1) IL172615A0 (OSRAM)
IS (1) IS8257A (OSRAM)
MX (1) MXPA05013460A (OSRAM)
MY (1) MY138680A (OSRAM)
NO (1) NO20060444L (OSRAM)
NZ (1) NZ544208A (OSRAM)
PL (1) PL1644340T3 (OSRAM)
PT (1) PT1644340E (OSRAM)
RU (1) RU2351595C2 (OSRAM)
SA (1) SA04250224B1 (OSRAM)
SE (1) SE0301922D0 (OSRAM)
SI (1) SI1644340T1 (OSRAM)
TW (1) TW200524898A (OSRAM)
UA (1) UA81491C2 (OSRAM)
UY (1) UY28387A1 (OSRAM)
WO (1) WO2005000822A1 (OSRAM)
ZA (1) ZA200510458B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427403D0 (en) 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
RS52229B (sr) * 2005-10-26 2012-10-31 Merck Serono Sa. Derivati sulfonamida i njihova upotreba za modulaciju metaloproteinaza
CN101007794B (zh) * 2006-01-26 2010-09-01 中国科学院上海药物研究所 N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
KR101822444B1 (ko) * 2010-07-08 2018-01-26 가켄 세이야쿠 가부시키가이샤 N-히드록시포름아미드 유도체 및 그를 함유하는 의약

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL200418B1 (pl) * 1998-01-30 2009-01-30 Darwin Discovery Ltd Pochodna N-hydroksyformamidu, zawierający ją środek farmaceutyczny i jej zastosowanie
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
KR20020005769A (ko) * 1999-06-04 2002-01-17 다비드 에 질레스 메탈로프로테이나제의 억제제
MXPA02008111A (es) * 2000-02-21 2002-11-29 Astrazeneca Ab N-hidroxiformamidas substituidas con piperidina y piperazina como inhibidores de metaloproteinasas.
GB0119472D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
BR0309671A (pt) * 2002-04-25 2005-05-03 Pharmacia Corp ácidos de piperidinil- e piperazinil-sulfonilmetil hidroxâmicos e seu uso como inibidores de protease
JP2006527754A (ja) * 2003-06-19 2006-12-07 セルテック アール アンド ディ リミテッド Cd23分断阻害物質としてのヒドロキサム酸スルホンアミド

Also Published As

Publication number Publication date
US20070197542A1 (en) 2007-08-23
PT1644340E (pt) 2009-01-02
RU2351595C2 (ru) 2009-04-10
IL172615A0 (en) 2006-04-10
DE602004017733D1 (de) 2008-12-24
CN102229589A (zh) 2011-11-02
SE0301922D0 (sv) 2003-06-27
TW200524898A (en) 2005-08-01
ATE414063T1 (de) 2008-11-15
NO20060444L (no) 2006-03-22
ZA200510458B (en) 2007-03-28
HK1086835A1 (en) 2006-09-29
CA2529468A1 (en) 2005-01-06
SI1644340T1 (sl) 2009-02-28
CY1108757T1 (el) 2014-04-09
AU2004251104B2 (en) 2008-05-08
MXPA05013460A (es) 2006-03-09
PL1644340T3 (pl) 2009-04-30
JP4701167B2 (ja) 2011-06-15
MY138680A (en) 2009-07-31
BRPI0411929A (pt) 2006-08-15
WO2005000822A1 (en) 2005-01-06
CN1812974A (zh) 2006-08-02
CN1812974B (zh) 2011-06-29
ES2315675T3 (es) 2009-04-01
JP2007516164A (ja) 2007-06-21
AR044931A1 (es) 2005-10-12
IS8257A (is) 2006-01-23
NZ544208A (en) 2009-02-28
SA04250224B1 (ar) 2009-05-31
DK1644340T3 (da) 2009-02-02
UY28387A1 (es) 2005-01-31
EP1644340B1 (en) 2008-11-12
RU2005141058A (ru) 2006-07-27
HRP20090009T3 (en) 2009-02-28
AU2004251104A1 (en) 2005-01-06
UA81491C2 (en) 2008-01-10
EP1644340A1 (en) 2006-04-12
KR20060026440A (ko) 2006-03-23
US7485644B2 (en) 2009-02-03

Similar Documents

Publication Publication Date Title
AR036046A1 (es) Inhibidores de la hiv proteasa, composiciones que las contienen y sus usos farmaceuticos
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PE20050232A1 (es) Metodo y composiciones para tratar la artritis reumatoide
ES2436020T3 (es) Derivados de sulfonamida sustituidos
AR040773A1 (es) Pirazoles utiles como inhibidores de gsk-3
ES2167959T3 (es) Nafto(2,1-b)piranos fotocromicos fusionados con indeno.
EA200801828A2 (ru) Соединения 1,2,4,5-тетрагидро-3h-бензазепина, способ их получения и фармацевтические композиции, содержащие эти соединения
PE20090042A1 (es) Analogos de ciclopamina
AR055150A1 (es) Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso
AR038536A1 (es) N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
CO6331462A2 (es) Compuesto de fenil pirrol o una sal farmaceuticamente aceptable del mismo con actividad activadora de la glucoquinasa
AR049578A1 (es) Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas
AR043487A1 (es) Heterociclos fusionados de pirimidina y usos de los mismos
MX2019007684A (es) Compuesto novedoso y sal de este aceptable desde el punto de vista farmacologico.
AR042362A1 (es) Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen
AR042910A1 (es) Compuestos de pirazolopirimidina y procedimiento para preparar el mismo y composiciones farmaceuticas que los contienen
RU2220953C2 (ru) Ненасыщенные производные гидроксимовой кислоты в качестве ингибиторов nadnad+ - adp-рибозилтрансферазы
PE20020426A1 (es) ß-TIO-a-AMINOACIDOS, PROCEDIMIENTOS PARA SU PREPARACION Y MEDICAMENTOS QUE LOS CONTIENEN
AR042887A1 (es) Derivados de diarilmetiden piperidina preparaciones y usos de los mismos
AR054031A1 (es) Compuestos acilaminobiciclicos ligandos de receptores cannabinoides
CY1108757T1 (el) Ενωσεις ν-{'4-υποκατεστημενη πιπεραζινη-1-σουλφονυλμεθυλαλκυλ}-ν-υδροξυφορμαμιδιου ως αναστολεις της μεταλλοπρωτεϊνασης.
CO5650235A2 (es) Derivados de imidazol
PE20201148A1 (es) Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
EA200600760A1 (ru) Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их
AR031662A1 (es) Nuevos derivados biciclicos de aminopirazinonas, su procedimiento de preparacion, composiciones farmaceuticas que las contienen y su utilizacion como inhibidores de proteasas de serina relacionadas con la tripsina

Legal Events

Date Code Title Description
FG Application granted
FD Application lapsed